

OPEN CALL FOR PAPERS

Advances in the pharmacotherapy of neuropathic pain: current challenges and future prospects

Pharmadvances, the e-journal of the Italian Society of Pharmacology - SIF

Guest Editors

Dr. Francesco De Logu (Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy), Dr. Elena Lucarini (University of Florence, Italy).

Co-Editors

Dr. Giulia Magni (University of Milan, Italy), Dr. Giada Amodeo (University of Milan, Italy), Dr. Serena Boccella (University of Campania Naples, Italy), Dr. Sara Ilari (University 'Magna Graecia' of Catanzaro, Italy).

Special Issue information

Neuropathic pain is a multidimensional and disabling health condition affecting 7-10% of the general population; its incidence is likely to increase due to the rising age of the global population. Multiple causes of neuropathic pain have been described and they converge into pain originating from a lesion or disease of the central or peripheral somatosensory nervous system, including brain and spinal cord injury, neurodegenerative diseases, multiple sclerosis, diabetes, HIV infection, leprosy, chemotherapeutics, alcohol abuse. The maladaptive response of the complex cell network involved in the transmission and perception of pain dramatically upsets the nociceptive system as well as the physiological substrate of classical painkiller drugs. Despite recent advances in the identification of pain-generating mechanisms and the introduction of evidence-based treatment guidelines, patients suffering from neuropathic pain are difficult to manage. The lack of effective and safe therapies for the treatment of the pain condition, requires many efforts for the medical community to study novel molecular and cellular targets and develop new therapeutic strategies for ameliorating patient's quality of life. This Special Issue aims to collect Review and Original papers about innovative and suitable pharmacological approaches to relieve neuropathic pain as single therapy or as adjuvant to other pain medications.

You can submit your manuscript directly to: <https://www.editorialmanager.com/phadv/default.aspx>.

Contact the Editorial Office for all the information you may need to complete your manuscript's submission at editorialoffice@pharmadvances.com

This is an open invitation, and we would be gratified if you would share this information with your colleagues and friends. We thank you in advance for your attention and look forward to hosting your paper on **Pharmadvances**.

OPEN CALL FOR PAPERS - COVID-19 pandemic

Pharmadvances, the e-journal of the Italian Society of Pharmacology - SIF

The social impact of the new coronavirus disease (COVID-19) pandemic is multifaceted and affected every area of pharmacology.

Pharmadvances, the official journal of the **Italian Society of Pharmacology (SIF)** with its **Editor in Chief Luca Pani** and its publisher **Edra** wants to publish an issue on COVID-19 and its pharmacology.

From its first launch, the journal has worked hard to guarantee itself a high level, challenging the new scientific frontiers. This is why, during 2020, it dedicated most of its issues to the hot **topic** of Medical Devices made of substances, mental diseases, and the role of Medical Societies during the COVID-19 epidemic experience, searching for new horizons and opportunities (**learn more at: www.pharmadvances.com**).

Now, it is your time to make the difference: scientific research requires a wide lens to encompass the whole pharmacological field and its latest updates. Indeed, a global challenge like the current Covid-19 pandemic can only be defeated when research results are rapidly and openly shared.

***We would like to encourage you all to submit to the journal papers focused on the new horizon of Pharmacology against the Covid-19 pandemic.
We are looking forward to hearing from you.***

The journal accepts **Research Articles, Opinion Papers, Reviews** and **Posters** (Post-it in Pharmacology). All papers will be subjected to the normal rapid peer revision by an international forum of independent experts.

You can submit your manuscript directly to: <https://www.editorialmanager.com/phadv/default.aspx> .
Contact the Editorial Office for all the information you may need to complete your manuscript's submission at editorialoffice@pharmadvances.com

This is an open invitation, and we would be gratified if you would share this information with your colleagues and friends. We thank you in advance for your attention and look forward to hosting your paper on **Pharmadvances**.

CALL FOR PAPERS

Pharmadvances, the e-journal of the Italian Society of Pharmacology - SIF

The official journal of the **Italian Society of Pharmacology (SIF)** with its **Editor in Chief Luca Pani** and published by **Edra**, has started its Call for Papers, moving towards the new articles for **Pharmadvances**.

From its first launch, the journal has worked hard to guarantee itself a high level, challenging the new scientific frontiers. This is why during the 2020, it dedicated most of its issues to the hot topic of Medical Devices made of substances, mental diseases and the role of Medical Societies during the COVID-19 epidemic-experience, searching for new horizons and opportunities ([learn more at: www.pharmadvances.com](http://www.pharmadvances.com)).

Now, it is your time to make the difference, to contribute concretely to the scientific community and the pharmacological field, so we would like to encourage you all to submit your papers to the journal.

The journal accepts **Research Articles, Opinion Papers, Reviews** and **Posters** (Post-it in Pharmacology). All papers will be subjected to the **double blind peer revision** by an international forum of independent experts.

You can submit your manuscript directly to: <https://www.editorialmanager.com/phadv/default.aspx> . Contact the Editorial Office for all the information you may need to complete your manuscript's submission at editorialoffice@pharmadvances.com

This is an open invitation, and we would be gratified if you would share this information with your colleagues and friends. We thank you in advance for your attention and look forward to hosting your paper on **Pharmadvances**.